Takeaway
- Regular use of proton pump inhibitors (PPIs) was not associated with an increased risk of all-cause and cause-specific mortality.
Why this matters
- In clinical practice, there is no reason to discontinue PPI use for a valid indication because of concerns about increased mortality.
- The potential long-term effects other than mortality are yet to be determined.
Study design
- A prospective population-based cohort study of 440,840 participants (38,065 PPI users; 402,775 PPI non-users) from the UK Biobank.
- Independent associations between regular PPI use and the risk of all-cause and cause-specific mortality were evaluated.
- Funding: National Natural Science Foundation of China and others.
Key results
- Over a median follow-up of 5.9 years, 13,154 deaths were reported.
- After adjusting for confounders, regular PPI use vs no use was not significantly associated with an increased risk of all-cause mortality (adjusted HR [aHR], 1.05; 95% CI, 0.97-1.13).
- Regular PPI use vs no use was not significantly associated with a higher risk of mortality from (aHR; 95% CI):
- neoplasms (1.06; 0.97-1.15);
- circulatory system diseases (0.96; 0.83-1.10);
- respiratory system diseases (1.10; 0.90-1.35);
- digestive system diseases (1.23; 0.90-1.68);
- external causes (1.12; 0.79-1.59); and
- other causes (1.14; 0.96-1.36).
Limitations
- Potential misclassification of PPI exposure.
This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.
